Outcome	No. of studies	No. of participants	Statistical method	Effect size	Vaccine efficacy (95% CI)
Confirmed SARS‐CoV‐2 infection after complete vaccination	N/A	N/A	N/A	N/A	N/A
Confirmed symptomatic COVID‐19 after complete vaccination	N/A	N/A	N/A	N/A	N/A
Severe or critical COVID‐19 after complete vaccination	N/A	N/A	N/A	N/A	N/A
All‐cause mortality	1	28,254	Risk Ratio (M‐H, Random, 95% CI)	1.27 (0.52 to 3.05)	N/A
Serious adverse events	N/A	N/A	N/A	N/A	N/A
Systemic reactogenicity events	1	119	Risk Ratio (M‐H, Random, 95% CI)	1.80 (0.71 to 4.56)	N/A
Any adverse event	N/A	N/A	N/A	N/A	N/A
Local reactogenicity events	1	119	Risk Ratio (M‐H, Random, 95% CI)	6.46 (3.18 to 13.13)	N/A